Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Pabst

Showing results (131-140 of 332) with videos related to

Pageof 34
Sort By:
BMC Cancer|April 15, 2023
Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patientsDilara Akhoundova Sanoyan, Katja Seipel, Ulrike Bacher, et al.
The Journal of Applied Laboratory Medicine|May 24, 2020
Serum Free Light Chain Assay: Shift Toward a Higher κ/λ RatioBarbara Rindlisbacher, Christof Schild, Florence Egger, et al.
Science Translational Medicine|September 6, 2013
Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemiaKatrin L Gutbrodt, Christoph Schliemann, Leonardo Giovannoni, et al.
Pediatric Radiology|December 6, 2012
Small-bowel MRI in children and young adults with Crohn disease: retrospective head-to-head comparison of contrast-enhanced and diffusion-weighted MRIHenning Neubauer, Thomas Pabst, Anke Dick, et al.
Leukemia & Lymphoma|August 22, 2015
Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicityBeatrice U Mueller, Sandra Keller, Katja Seipel, et al.
Hemasphere|December 4, 2023
CAR-T Cell Therapy Shows Similar Efficacy and Toxicity in Patients With DLBCL Regardless of CNS InvolvementEvgenii Shumilov, Hristo Boyadzhiev, Paolo Mazzeo, et al.
Hemasphere|November 15, 2019
Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML PatientsBianca R Schnell, Katja Seipel, Ulrike Bacher, et al.
Bone Marrow Transplantation|April 29, 2021
Lack of association of travel time to transplant center and posttransplant care model with outcome parameters after allogeneic transplantationRaffaele Peter, Joerg P Halter, Dominik Heim, et al.
Haematologica|June 16, 2018
Pitfalls in the molecular follow up of <i>NPM1</i> mutant acute myeloid leukemiaUlrike Bacher, Naomi Porret, Raphael Joncourt, et al.
Biomedicines|July 27, 2024
Gemtuzumab Ozogamicin and Stem Cell Mobilization for Autologous Stem Cell Transplantation in Favorable Risk Acute Myeloid LeukemiaDanaë Martinez Flores, Dilara Akhoundova, Katja Seipel, et al.
Pageof 34

Showing results (131-140 of 332) with videos related to

Sort By:
Pageof 34
BMC Cancer|April 15, 2023
Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patientsDilara Akhoundova Sanoyan, Katja Seipel, Ulrike Bacher, et al.
The Journal of Applied Laboratory Medicine|May 24, 2020
Serum Free Light Chain Assay: Shift Toward a Higher κ/λ RatioBarbara Rindlisbacher, Christof Schild, Florence Egger, et al.
Science Translational Medicine|September 6, 2013
Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemiaKatrin L Gutbrodt, Christoph Schliemann, Leonardo Giovannoni, et al.
Pediatric Radiology|December 6, 2012
Small-bowel MRI in children and young adults with Crohn disease: retrospective head-to-head comparison of contrast-enhanced and diffusion-weighted MRIHenning Neubauer, Thomas Pabst, Anke Dick, et al.
Leukemia & Lymphoma|August 22, 2015
Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicityBeatrice U Mueller, Sandra Keller, Katja Seipel, et al.
Hemasphere|December 4, 2023
CAR-T Cell Therapy Shows Similar Efficacy and Toxicity in Patients With DLBCL Regardless of CNS InvolvementEvgenii Shumilov, Hristo Boyadzhiev, Paolo Mazzeo, et al.
Hemasphere|November 15, 2019
Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML PatientsBianca R Schnell, Katja Seipel, Ulrike Bacher, et al.
Bone Marrow Transplantation|April 29, 2021
Lack of association of travel time to transplant center and posttransplant care model with outcome parameters after allogeneic transplantationRaffaele Peter, Joerg P Halter, Dominik Heim, et al.
Haematologica|June 16, 2018
Pitfalls in the molecular follow up of <i>NPM1</i> mutant acute myeloid leukemiaUlrike Bacher, Naomi Porret, Raphael Joncourt, et al.
Biomedicines|July 27, 2024
Gemtuzumab Ozogamicin and Stem Cell Mobilization for Autologous Stem Cell Transplantation in Favorable Risk Acute Myeloid LeukemiaDanaë Martinez Flores, Dilara Akhoundova, Katja Seipel, et al.
Pageof 34